Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.

• Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
• Correlation analysis of KRAS mutation results with clinical data.

Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

• Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
• A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
• Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.

Inclusion Criteria:

• Patients with pathologically confirmed pancreatic adenocarcinoma.

Exclusion Criteria:

• Patients disagree with the study.